Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Active:	No
Cancer Type:	Neuroblastoma	NCT ID:	NCT02650401
Trial Phases:	Phase I Phase II	Protocol IDs:	RXDX-101-03 (primary) NCI-2016-00924
Eligibility:	0 - 18 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT02650401

Summary

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with
relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts
(Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and
extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.